<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0008282'>Unconjugated hyperbilirubinemia</z:hpo> results from <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> and from antiretroviral therapy (ART) containing <z:chebi fb="0" ids="37670">protease inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>An understanding of the interaction between genetic predisposition and ART may help to identify individuals at highest risk for developing <z:hpo ids='HP_0000952'>jaundice</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We quantified the contribution of UGT1A1*28 and ART to <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> by longitudinally modeling 1386 total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in 96 human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV)-infected individuals during a median of 6 years </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The estimated average <z:chebi fb="0" ids="16990">bilirubin</z:chebi> level was 8.8 micromol/L (0.51 mg/dL) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="37924">Atazanavir</z:chebi> <z:hpo ids='HP_0003573'>increased bilirubin</z:hpo> levels by 15 mu mol/L (0.87 mg/dL), and <z:chebi fb="0" ids="44032">indinavir</z:chebi> <z:hpo ids='HP_0003573'>increased bilirubin</z:hpo> levels by 8 micromol/L (0.46 mg/dL) </plain></SENT>
<SENT sid="5" pm="."><plain>Ritonavir, lopinavir, saquinavir, and nelfinavir had no or minimal effect on <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>Homozygous UGT1A1*28 <z:hpo ids='HP_0003573'>increased bilirubin</z:hpo> levels by 5.2 micromol/L (0.3 mg/dL) </plain></SENT>
<SENT sid="7" pm="."><plain>As a consequence, 67% of individuals homozygous for UGT1A1*28 and receiving <z:chebi fb="0" ids="37924">atazanavir</z:chebi> or <z:chebi fb="0" ids="44032">indinavir</z:chebi> had &gt; or =2 episodes of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in the <z:hpo ids='HP_0000952'>jaundice</z:hpo> range (&gt;43 micromol/L [&gt;2.5 mg/dL]), versus 7% of those with the common allele and not receiving either of those <z:chebi fb="0" ids="37670">protease inhibitors</z:chebi> (P&lt;.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Efavirenz resulted in decreased <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels, which is consistent with the induction of <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase 1A1 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Genotyping for UGT1A1*28 before initiation of ART would identify HIV-infected individuals at risk for <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> and decrease episodes of <z:hpo ids='HP_0000952'>jaundice</z:hpo> </plain></SENT>
</text></document>